Brief: Kymera Therapeutics Q3 EPS USD -0.82 Vs. IBES Estimate USD -0.84
31/10/2024 11:30
Oct 31 (Reuters) - Kymera Therapeutics Q3 net income USD -62.487 million vs. IBES estimate USD -62.9 million. * Q3 operating expenses USD 75.865 million * Q3 revenue USD 3.741 million vs. IBES estimate USD 10.4 million
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer